Navigation Links
Boston Scientific Announces FDA Approval and U.S. Launch of PROMUS® 2.25 mm Everolimus-Eluting Coronary Stent System
Date:5/25/2011

NATICK, Mass., May 25, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has received approval from the U.S. Food and Drug Administration (FDA) to market its 2.25 mm PROMUS® Everolimus-Eluting Coronary Stent System for use in vessels as small as 2.25 mm in diameter.  The Company plans to immediately launch the product in the U.S.

The PROMUS Stent features a thin-strut, open-cell design to allow for excellent flexibility and conformability in the vessel.  The low-profile stent and catheter tip help enhance deliverability, especially in small vessels.  The PROMUS Stent is supported by the SPIRIT clinical trial program, which demonstrates that the controlled release of everolimus results in low levels of late loss and a strong safety profile.  The addition of this stent expands the available size matrix of Boston Scientific's PROMUS Stent portfolio to include diameters from 2.25 to 4.0 mm and lengths from 8 mm to 28 mm.

"The PROMUS Stent has demonstrated outstanding deliverability, low late loss and excellent safety in numerous clinical trials and extensive real-world practice," said Dean J. Kereiakes, M.D., FACC, Medical Director, The Christ Hospital Heart and Vascular Center and The Carl and Edyth Lindner Center for Research and Education at The Christ Hospital, and Professor of Clinical Medicine, Ohio State University.  "These benefits make the PROMUS 2.25 mm Stent an attractive option for U.S. physicians treating patients with small vessels."

"The approval of the 2.25 mm PROMUS Stent further expands our leading drug-eluting stent portfolio, which includes both everolimus and paclitaxel-eluting stents for the treatment of small vessels and long lesions," said Hank Kucheman, Executive Vice President and Group President, Cardiology, Rhythm and Vascular for Boston Scientific.  "In 2008,
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Boston Scientific Announces Schedule for European Society of Cardiology Congress 2007
3. Boston University Biomedical Engineers Find Chink in Bacterias Armor
4. Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 2007
5. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
6. Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures
7. Boston Scientifics Next-Generation Stent Shows Improved Clinical Outcomes in Complex Lesions
8. Positive Five-Year Safety Data for TAXUS(R) Stent Reported in Boston Scientific Trial
9. Boston Scientific Carotid Artery Stenting Trials Produce Positive Three-Year Results
10. Award-Winning Medicine Wheel Returns to the Cyclorama at the Boston Center for the Arts on Dec. 1 for 24-hour Vigil Recognizing World AIDS Day
11. Boston Scientific Announces CE Mark Approval for New Devices to Treat Heart Failure and Sudden Cardiac Death
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... 2013 /PRNewswire-iReach/ -- World markets are constantly changing ... trends and events, companies now need a global ... industry is headed next, so that they can ... http://photos.prnewswire.com/prnh/20130522/CG19099 ) Global Information Inc ... GlobalData, offer decision makers and executives integrated business ...
(Date:5/22/2013)... , May 22, 2013  Viral hepatitis is an asymptomatic ... percent of those with hepatitis C are unaware they have ... and Awareness Day in the U.S. House of Representatives will ... Rayburn Foyer of the Rayburn House Office Building in ... Association for the Study of Liver Diseases ( AASLD ) ...
(Date:5/22/2013)... N.Y. , May 22, 2013  The Leukemia ... million to Valor Biotherapeutics, LLC, a joint venture ... pre-clinical development, manufacturing, and a Phase I clinical trial ... poor outcomes faced by many patients with indolent lymphomas ... Valor,s protein, IGN002, is a new ...
Breaking Medicine Technology:Adapt, React, Evolve: Staying Ahead in the Breast Cancer Gene Testing, Solar Energy, and Oil & Gas Markets with Reliable Analytics and Actionable Insights from GlobalData's 700 Market Analysts 2Adapt, React, Evolve: Staying Ahead in the Breast Cancer Gene Testing, Solar Energy, and Oil & Gas Markets with Reliable Analytics and Actionable Insights from GlobalData's 700 Market Analysts 3Adapt, React, Evolve: Staying Ahead in the Breast Cancer Gene Testing, Solar Energy, and Oil & Gas Markets with Reliable Analytics and Actionable Insights from GlobalData's 700 Market Analysts 4Hepatitis Awareness: Bringing Attention to a Silent Epidemic 2The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients 2The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients 3The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients 4
... 2007 - Rexahn,Pharmaceuticals, Inc. (OTC BB:RXHN), a ... commercialization of,innovative treatments for cancer, central nervous ... needs, today announced,that Dr. John Marshall, Principal ... Company's lead cancer compound RX-0201 (Archexin),will present ...
... Clinical Trials for Organ Transplantation, HORSHOLM, Denmark, May ... I clinical results for,its transplantation product candidate, LCP-Tacro ... organ transplantation. , Today LifeCycle Pharma A/S (OMX:LCP) ... program of LCP-Tacro, a,proprietary, once-daily tacrolimus tablet. , ...
Cached Medicine Technology:LifeCycle Pharma Announces Positive Phase I Clinical Results for,its Transplantation Product Candidate, LCP-Tacro 2LifeCycle Pharma Announces Positive Phase I Clinical Results for,its Transplantation Product Candidate, LCP-Tacro 3
(Date:5/22/2013)... Boise, ID (PRWEB) May 22, 2013 ... us. This Memorial Day (May 27, 2013) Bodybuilding.com will be ... regardless of the amount. , “We are extremely grateful ... in the Armed Forces,” said Ryan DeLuca, CEO and founder ... nations heroes who have sacrificed so much. Hire Heroes USA ...
(Date:5/22/2013)... ARBORA University of Michigan study challenges previous research ... Baseball. , The study, a collaboration between researchers ... Florida, looks deeper into the controversial argument over ... strikes for pitchers of the same race. It ... said Jason Winfree, associate professor of sport management ...
(Date:5/22/2013)... 22, 2013 Award Presented at the ... press release here: http://bit.ly/13DkFfk , Merrill Corporation ... “Information Management Product/Service of the Year” at the 7th ... The Colony Hotel in Palm Beach, Florida. , ... room (VDR) solution that optimizes the due diligence ...
(Date:5/22/2013)... Space Girl Organics is excited to ... weekend's I Talk to Strangers Miracle Run/Walk . The ... Riverside Park in Cocoa, FL. The event aims to “create ... social movement. , As a sponsor, Space Girl Organics is ... the event. Additionally, they are providing bananas for runners and ...
(Date:5/22/2013)... Go Classy the Original Nudist Travel Agent and ... newest website http://www.Desire-Mexico.com . The seductively liberating couples ... have become the premier Nudist and Lifestyle Vacation destination. ... while allowing you to enjoy a deluxe all inclusive ... / Caribbean-Hideaways. He goes on to say "Desire Resorts ...
Breaking Medicine News(10 mins):Health News:In the Spirit of Memorial Day, Bodybuilding.com is Donating a Portion of Their Sales to Hire Heroes 2Health News:U-M study challenges notion that umpires call more strikes for pitchers of same race 2Health News:Merrill DataSite New Press Release: Merrill DataSite® Virtual Data Room Honored as “Information Management Product/Service of the Year” 2Health News:Merrill DataSite New Press Release: Merrill DataSite® Virtual Data Room Honored as “Information Management Product/Service of the Year” 3Health News:Space Girl Organics to Sponsor May 25 Miracle Run/Walk 2Health News:Go Classy Tours Announces the Launch of Their Newest Website for Desire Resorts Located in Mexico Clothing Optional/Aunaturel Resorts a Lovers Paradise 2
... genetically modified maize developed by U.S. biotech giant Monsanto, ... developed liver and kidney problems. ,Greenpeace said ... the journal Archives of Environmental Contamination and Technology showed ... showed "signs of toxicity" in the liver and kidneys. ...
... an eye each allegedly due to medical neglect after ... were to blame because they had not taken adequate ... cataract operation camp at the government hospital at Bhabanipatna ... operated upon, all above 60 years. ,Six ...
... The Dr Reddy's Laboratories (DRL), a leading Indian pharmaceutical firm, ... all-in-one polypill// for heart problems on 250 patients in the ... put it in the market by the end of this ... for dilating arteries, relaxing heart muscles, removing excess water and ...
... casein proteins reduced the development of eczema by 33 ... ,"The 3-year results of this large-scale, prospective, randomized, ... for [atopic dermatitis] AD but not for early asthma ... high risk for allergic diseases," wrote lead author Andrea ...
... in Britain indicates that the salt intake of the Britishers has ... Health experts opine that cardiac arrests and strokes can be prevented ... the report, there is a decrease of salt consumption from 9.5g ... cut down their salt intake from 11g to 10.2g while in ...
... London have shown how the brain makes sense of speech ... a crowd. // The research suggests that various regions of ... hears, but that when the speech is completely incomprehensible, the ... was intended to simulate the everyday experience of people who ...
Cached Medicine News:Health News:Hydrolysed Casein Formula may Slash Eczema in Infants 2Health News:Making Sense of the World Through a Cochlear Implant 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: